Pharmafile Logo
Pharmafocus logo
Advanced Search

tofacitinib

Showing 14 posts of 14 posts found.

Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study

November 12, 2019
Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib

Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …

News

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

July 29, 2016
Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …

News
pfizerbrussels

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …

News
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

News
pfizer_logo

Pfizer’s Xeljanz denied plaque psoriasis indication by FDA

October 16, 2015
Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib

The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …

News

Pfizer, Novartis and Celgene among late-stage psoriasis trial advances

March 23, 2015
Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib

Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

News
pfizer image

Mixed tale for Pfizer psoriasis drug

October 11, 2013
Sales and Marketing Enbrel, Pfizer, psoriasis, tofacitinib

Pfizer has seen its novel, oral Janus kinase (JAK) inhibitor tofacitinib turn in a mixed showing in late-stage trials in …

News

New data for Pfizer arthritis pill

September 18, 2012
Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib

Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …

News

Pfizer’s arthritis drug delayed by FDA

August 21, 2012
Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib

Pfizer says its new rheumatoid arthritis drug tofacitinib has been delayed by the FDA. Tofacitinib, an oral Janus kinase (JAK) …

News

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

News

FDA accepts Pfizer’s arthritis pill for review

December 22, 2011
Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib

The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …

News

EMA accepts submission of Pfizer’s new arthritis drug

November 21, 2011
Research and Development, Sales and Marketing EMA, Pfizer, tofacitinib

The European Medicines Agency has accepted Pfizer’s arthritis drug tofacitinib for review.Tofacitinib is a novel, oral JAK inhibitor being studied …

News
Pfizer

Deaths reported in Pfizer arthritis trial

April 26, 2011
Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …

News
Pfizer

Phase III boost for Pfizer’s oral arthritis drug

April 18, 2011
Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023